San Diego Anti-aging medicine and family practice located in Encinitas CA, Center for Age Management

Optimize Your Health
Center for Age Management

317 N. El Camino Real, Suite 206
Encinitas, CA 92024
USA View Map

Phone: 760-633-1315


Mon - Thur: 9am to 5pm
Lunch: 12pm to 1:30pm
Friday: 9am to 12pm
On Fridays, we will have limited staff. You may leave a message and it will be our pleasure to return your call. Any prescriptions, questions or concerns that you have, we will be happy to assist you Monday - Thursday.

Serving other neighboring cities: La Costa, Solana Beach, Rancho Santa Fe, Del Mar, San Marcos, Carlsbad, La Jolla, and San Diego County, CA.

Effects of (GH) and Insulin-Like Growth Factor 1 on Prostate

Effects of Growth Hormone (GH) and Insulin-Like Growth Factor 1 on Prostate Disease: An Ultrasonographic and Endocrine Study in Acromegaly, GH Deficiency, and Healthy Subjects
The role of insulin-like growth factor 1 (IGF-1) in prostate development is currently under thorough investigation because it has been claimed that IGF-1 is a positive predictor of prostate cancer.
To assess the effect of GH and IGF-1 levels on prostate pathophysiology, 46 acromegalic (30 in active disease, ten cured from acromegaly, and six affected from GH deficiency) and 30 aged-matched male controls, free from previous or concomitant prostate disorders, underwent pituitary, androgen, and prostate hormonal assessments and transrectal ultrasonography. Compared to control values, GH (P<0.0001), IGF-1 (P<0.0001), and IGFBP-3 (P<0.001) levels were increased, whereas testosterone (P<0.0001) and dihydrotestosterone levels (P<0.0001) were reduced in active acromegalic patients. Hypogonadism was present in 28 of the 46 acromegalic patients (60.8%). The anteroposterior (P<0.05), and transverse (P<0.0001) prostate diameters and the transitional zone volume (P<0.05) were increased in acromegalic patients compared to those in controls. Prostate volume (PV) was significantly higher in untreated acromegalic patients than in controls (41.7 + 3.2 vs. 21.9 + 1.4 mL; P<0.0001), cured patients (23.6 + 1.6 mL; P<0.0001), and GH-deficient patients (17.5 + 1.1 mL; P<0.0001). In the patients, PV was correlated with disease duration (r=0.606; P<0.0001) and age (r=0.496; P<0.0001), whereas in controls it was correlated with age (r=0.476; P<0.01) and IGF-1 levels (r=-0.448; P<0.05). Benign prostate hyperplasia (PV > 30 mL) was found in 58% of the acromegalics and 26.6% of the controls. When grouped by age (<40, 40-60, and >60 yr), PV was increased in elderly patients compared to younger patients (P<0.05) and to controls (P<0.01). The prevalence of structural abnormalities, including calcifications, nodules, cysts, and vesicle inflammation, was significantly increased in patients compared to controls (78.2% vs. 23.3%; x2= 5.856; P<0.05). No clinical, transrectal ultrasonography, or cytological evidence of prostate cancer was detected in acromegalic or control subjects. In conclusion, chronic excess of GH and IGF-1 cause prostate overgrowth and further phenomena of rearrangement, but not prostate cancer.